ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 HKD | -4.64% |
|
+18.52% | -56.63% |
| 06-05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
| 06-05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 373M | - | |||||
| 59.34B | - | |||||
| 40.24B | ||||||
| 39.88B | ||||||
| 28.55B | ||||||
| 27.26B |
- Stock Market
- Equities
- 9966 Stock
- Charts Alphamab Oncology
- Sector Chart
